Moncef Slaoui is a partner at Medicxi, having joined the firm in September 2017. Aside from Divide & Conquer he has an active role in several other Medicxi portfolio companies.
Prior to Medicxi, Moncef was GlaxoSmithKline’s Head of Pharmaceutical R&D and Chairman of its Vaccines division. From this leadership role, Moncef spearheaded a profound overhaul of GSK's pharmaceutical R&D, resulting in a substantial improvement in productivity, a late-stage pipeline comprising more than 30 phase 3 programmes and a totally redesigned discovery organisation comprising 38 highly-focused and accountable Discovery Performance Units. During his career at GSK, he also headed the development of a robust vaccines pipeline, including Rotarix to prevent infantile gastroenteritis, Synflorix to prevent pneumococcal disease and Cervarix to prevent cervical cancer.
Outside of his role at Medicxi and Medicxi portfolio companies, Moncef is chairman of the board at Galvani Bioelectronics, which was founded by GSK and Alphabet Inc. subsidiary Verily Life Sciences, chairman of the board at SutroVax, a venture-backed biopharma company, and sits on the boards of Artisan Biosciences, Human Vaccines Project and Moderna Therapeutics. His past board service includes PhRMA Foundation, Qatar Foundation, NIH Advisory Committee to the Director, and BIO.
Moncef earned a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. Formerly a professor of Immunology at the University of Mons in Belgium, Moncef has authored more than 100 scientific papers and presentations. He has been featured in FierceBiotech’s “25 most influential people in biopharma today” and in 2016 was one of FORTUNE magazine’s World's Greatest Leaders. A citizen of Morocco, Belgium and the US, he is fluent in Arabic, French and English.